Clopidogrel treatment surrounding percutaneous coronary intervention: When should it be started and stopped?
- 35 Downloads
Clopidogrel pretreatment before percutaneous coronary intervention (PCI) has been shown to decrease major adverse cardiovascular events (MACE) at 1 month. This benefit has been demonstrated in patients spanning the entire spectrum of coronary artery disease. Subsequent dual antiplatelet therapy with aspirin and clopidogrel after stent placement is necessary for the prevention of stent thrombosis. The duration of clopidogrel therapy after stent placement is dependent upon the type of stent placed, and is recommended for a minimum of 4 weeks after bare-metal stent placement, 3 months after sirolimus-eluting stent placement, and 6 months after paclitaxel-eluting stent placement. A longer course of therapy with clopidogrel (12 months) has been recommended by the most recent American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions guidelines for PCI based upon incremental reduction in cardiovascular complications (primarily myocardial infarction). This article reviews the data presently available regarding pretreatment with clopidogrel before PCI, and the strength of evidence supporting long-term dual antiplatelet therapy.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 6.• Leon MB, Baim DS, Popma JJ, et al.: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998, 339:1665–1671.Established the efficacy and safety of dual antiplatelet therapy versus systemic anticoagulationPubMedCrossRefGoogle Scholar
- 8.Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al.: ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006, 113:156–175.PubMedCrossRefGoogle Scholar
- 9.•• Mehta SR, Yusuf S, Peters RJ, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527–533.Substudy of the CURE trial establishing the efficacy of clopidogrel preload and long-term therapy in reducing cardiovascular events at long-term follow-up in patients undergoing stenting for ACSPubMedCrossRefGoogle Scholar
- 10.•• Steinhubl SR, Berger PB, Mann JT 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411–2420.First randomized trial demonstrating reduction in the combined endpoint of death, MI, and stroke in low-risk PCI patients treated with both a clopidogrel load and long-term therapyPubMedCrossRefGoogle Scholar
- 15.Patti G, Colonna G, Pasceri V, et al.: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2005, 111:2099–2106.PubMedCrossRefGoogle Scholar
- 24.Lemos PA, Serruys PW, van Domburg RT, et al.: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004, 109:190–195.PubMedCrossRefGoogle Scholar